Ibrutinib is a first-in-class, once-daily oral inhibitor of Bruton’s tyrosine kinase (BTK) approved in Europe as monotherapy for the treatment of adult patients with previously untreated and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) [1]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.